Amgen Inc DossierAmgen Inc reported total revenues of $8.2 billion for the second quarter of 2025, generating $1.9 billion in free cash flow driven by a 13% increase in product sales volume across its portfolio. The biotechnology leader continued to advance its commercial strategy through fifteen products delivering double-digit growth, including key performers such as Repatha, EVENITY, and TEZSPIRE. Financial Highlights* Q2 2025 Total Revenue: $8.2 billion * Full Year 2025 Revenue Guidance: $32.0 billion to $33.0 billion * Q2 2025 GAAP Earnings Per Share: $2.65 * Q2 2025 Non-GAAP Earnings Per Share: $5.02 * Full Year 2025 Non-GAAP EPS Guidance: $19.20 to $20.30 * Q2 2025 Free Cash Flow: $1.9 billion * Full Year 2025 Capital Expenditures Guidance: Approximately $1.3 billion * Q3 2025 Dividend Declared: $2.38 per share Amgen Inc continues to execute on a strategic framework centered on its innovative pipeline and the integration of Horizon Therapeutics. The company is prioritizing the development... Sign in / Sign up to learn more about Amgen Inc Continue your research by chatting with our AI financial analyst about Amgen Inc. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings. Start your analysis with these investor-focused questions: - Given Amgen Inc.'s FY2025 revenue guidance of $33.0 billion to $34.0 billion, what are the primary product drivers, such as Repatha® and EVENITY®, and potential headwinds, like biosimilar competition for Prolia®, that will determine its performance within this range?
- With the integration of Horizon Therapeutics underway, how will this acquisition likely impact Amgen Inc.'s key financial metrics in FY2025, specifically its non-GAAP operating margin target of approximately 51% and its leadership in the rare and inflammatory diseases market?
- Amgen Inc.'s pipeline candidate MariTide is positioned for the high-growth obesity market, with key Phase 2 data expected in Q4 2025. How do the potential outcomes of this trial affect Amgen Inc.'s long-term growth trajectory and competitive standing against established players?
- Considering Amgen Inc.'s forward P/E ratio of 14.71 and EV/Revenue multiple of 6.36, how does its valuation stack up against peers like Regeneron and Gilead, and what does this suggest about the market's expectations for its future growth versus execution risks?
- How is Amgen Inc. balancing its capital allocation strategy between funding growth initiatives like the MariTide program, managing debt from the Horizon acquisition, and sustaining shareholder returns, as evidenced by its Q3 2025 dividend of $2.38 per share?
|
